المؤلفون: A. I. Tarasenko, A. N. Rossolovskiy, O. L. Berezinets, A. B. Bucharskaya, S. S. Pakhomiy, A. O. Efimova, G. N. Maslyakova

المصدر: Issledovaniâ i Praktika v Medicine, Vol 9, Iss 2, Pp 96-106 (2022)

مصطلحات موضوعية: почечно-клеточный рак, ммр-9, резекция почки, биомаркеры, маркеры почечной функции, Medicine

وصف الملف: electronic resource

العلاقة: https://www.rpmj.ru/rpmj/article/view/806Test; https://doaj.org/toc/2410-1893Test

الوصول الحر: https://doaj.org/article/ca45c5570bbd44cc9557d5f1ee16f126Test

المؤلفون: D. N. Khotko, A. I. Khotko, A. I. Tarasenko, A. O. Efimova

المصدر: Issledovaniâ i Praktika v Medicine, Vol 9, Iss 2, Pp 133-142 (2022)

مصطلحات موضوعية: маркеры почечного повреждения, мочекаменная болезнь, биомаркеры почечной функции, Medicine

وصف الملف: electronic resource

العلاقة: https://www.rpmj.ru/rpmj/article/view/812Test; https://doaj.org/toc/2410-1893Test

الوصول الحر: https://doaj.org/article/e2f4e79ace7f4d26ba37bacef9a9cb5fTest

المؤلفون: O. Efimova V., M. Volkov A., D. Koroleva A., О. Ефимова B., М. Волков А., Д. Королёва А.

المصدر: Finance: Theory and Practice; Том 25, № 4 (2021); 82-97 ; Финансы: теория и практика/Finance: Theory and Practice; Том 25, № 4 (2021); 82-97 ; 2587-7089 ; 2587-5671 ; 10.26794/2587-5671-2021-25-4

مصطلحات موضوعية: sustainable development, responsible investment, ESG integration, portfolio analysis, return on investment, value drivers, ESG financial impact, G11, G32, G41, C12, C51, устойчивое развитие, ответственное инвестирование, ESG-интеграция, портфельный анализ, доходность инвестирования, драйверы ценности, финансовые последствия ESG

وصف الملف: application/pdf

العلاقة: https://financetp.fa.ru/jour/article/view/1279/851Test; https://financetp.fa.ru/jour/article/view/1279/852Test; Amel-Zadeh A., Serafeim G. Why and how investors use ESG information: Evidence from a global survey. Harvard Business School Working Paper. 2017;(79). URL: https://dash.harvard.edu/bitstream/handle/1/30838135/17-079.pdf?sequence=1&isAllowed=yTest; Лосева О. В., Федотова М.А. Оценка инвестиционной привлекательности социально-экономических субъектов. Имущественные отношения в Российской Федерации. 2021;(3):58-67. DOI:10.24411/2072-4098-2021-10304; Dhaliwal D. S. et al. Voluntary nonfinancial disclosure and the cost of equity capital: The initiation of corporate social responsibility reporting. The Accounting Review. 2011;86(1):59-100. DOI:10.2308/accr.00000005; Efimova O., Rozhnova O. Covid-19: Financial impact and disclosure. Comprehensible Science. 2021;186:205-213. DOI:10.1007/978-3-030-66093-2_20; Khan M., Serafeim G., Yoon A. Corporate sustainability: First evidence on materiality. The Accounting Review. 2015;91(6):1697-1724. DOI:10.2308/accr-51383; Efimova O. Integrating sustainability issues into investment decision. Journal of Reviews on Global Economics. 2018;7:668-681. DOI:10.6000/1929-7092.2018.07.61; Berg F., Kölbel J., Rigobon R. Aggregate confusion: The divergence of ESG ratings. SSRN Electronic Journal. 2019. DOI:10.2139/ssrn.3438533; Brundtland G. H. Our common future. Report of the International Commission on Environment and Development. 1989. URL: https://sustainabledevelopment.un.org/content/documents/5987our-commonfuture.pdfTest; Van Holt T., Whelan T. Research frontiers in the era of embedding sustainability: Bringing social and environmental systems to the forefront. Journal of Sustainability Research. 2021;3(2): e210010. DOI:10.20900/jsr20210010; Freemen R. E. Strategic management: A stakeholder approach. Cambridge: Cambridge University Press; 2010. 292 p.; Elkington J. Enter the triple bottom line. In: Henriques A., Richardson J., eds. The triple bottom line: Does it all add up? London, New York: Routledge; 2013:23-38.; Schoenmaker D., Schramade W. Principles of sustainable fi e. Oxford, New York: Oxford University Press; 2018. 432 p.; Cheng B., Ioannou I., Serafeim G. Corporate social responsibility and access to finance. Strategic Management Journal. 2014;35(1)1-23. DOI:10.1002/smj.2131; Clark G. L., Feiner A., Viehs M. From the stockholder to the stakeholder: How sustainability can drive financial outperformance. SSRN Electronic Journal. 2015. DOI:10.2139/ssrn.2508281; Busch T., Bauer R., Orlitzky M. Sustainable development and financial markets: Old paths and new avenues. Business and Society. 2016;55(3):303-329. DOI:10.1177/0007650315570701; Renshaw A.A. ESG’s evolving performance: First, do no harm. Frankfurt: Axioma, Inc.; 2018. 17 p.; Goss A., Roberts G. S. The impact of corporate social responsibility on the cost of bank loans. Journal of Banking & Finance. 2011;35(7):1794-1810. DOI:10.1016/j.jbankfin.2010.12.002; Gregory A., Tharyan R., Whittaker J. Corporate social responsibility and fi value: Disaggregating the effects on cash flow, risk and growth. Journal of Business Ethics. 2014;124(4):633-657. DOI:10.1007/s10551013-1898-5; Friede G., Busch T., Bassen A. ESG and financial performance: Aggregated evidence from more than 2000 empirical studies. Journal of Sustainable Finance and Investment, 2015;5(4):210-233. DOI:10.1080/20430795.2015.1118917; Cappucci M. The ESG integration paradox. Journal of Applied Corporate Finance. 2018;30(2):22-28. DOI:10.1111/jacf.12296; Eccles R. G., Kastrapeli M. D. The investing enlightenment. Boston, MA: State Street Corp.; 2017. 40 p. URL: https://arabesque.com/research/Final_The_Investing_Enlightenment.pdfTest; Van Burren E., Plantinga A., Scholtens B. ESG integration and the investment management process: Fundamental investing reinvented. Journal of Business Ethics. 2016;138(3):525-533. DOI:10.1007/s10551-015-2610-8; Melas D., Nagy Z., Kulkarni P. Factor investing and ESG integration. In: Jurczenko E., ed. Factor investing: From traditional to alternative risk premia. Amsterdam: Elsevier; 2017:389-413.; Visconti R. M. DCF metrics and the cost of capital: ESG drivers and sustainability patterns. 2021. URL: https://www.researchgate.net/publication/344953641Test; Ferrarese C., Hanmer J. The impact of ESG investing in corporate bonds. London: Fidelity International; 2018. 14 p. URL: https://page.ws.fidelityinternational.com/rs/829-LMVTest‑001/images/ESG%20White%20Paper%20FINAL.pdf; Whelan T., Atz U., Clark C. ESG and financial performance: Uncovering the relationship by aggregating evidence from 1,000 plus studies published between 2015-2020. New York: NYU STERN Center for sustainable business; 2021. 19 p. URL: URL: https://www.stern.nyu.edu/sites/default/files/assets/documents/NYU-RAM_ESG-Paper_2021.pdfTest; Sinha R., Datta M., Ziolo M. Inclusion of ESG factors in investments and value addition: A meta-analysis of the relationship. In: Tarczyński W., Nermend K., eds. Effective investments on capital markets. Cham: Springer International Publishing; 2019:93-109. DOI:10.1007/978-3-030-21274-2_7; Vishwanathan P. et al. Strategic CSR: A concept building meta-analysis. Journal of Management Studies. 2020;57(2):314-350. DOI:10.1111/joms.12514; Nagy Z., Kassam A., Lee L.-E. Can ESG add alpha? An analysis of ESG tilt and momentum strategies. The Journal of Investing. 2016;25(2):113-124. DOI:10.3905/joi.2016.25.2.113; Jo H., Na H. Does CSR reduce firm risk? Evidence from controversial industry sectors. Journal of Business Ethics. 2012;110(4):441-456. DOI:10.1007/s10551-012-1492-2; Krüger P. Corporate goodness and shareholder wealth. Journal of Financial Economics. 2015;115(2):304-329. DOI:10.1016/j.jfineco.2014.09.008; Hawken P. Socially responsible investing. How the SRI industry has failed to respond to people who want to invest with conscience and what can be done to change it. Sausalito, CA: Natural Capital Institute; 2004. 40 p. URL: https://community-wealth.org/sites/clone.community-wealth.org/files/downloads/report-harkin.pdfTest; Chatterji A., Durand R., Levine D. I., Touboul S. Do ratings of fi converge? Implications for managers, investors and strategy researchers. Strategic Management Journal. 2016;37(8):1597-1614. DOI:10.1002/smj.2407; Fernández M. S., Abu-Alkheil A., Khartabiel G. M. Do German green mutual funds perform better than their peers? Business and Economics Research Journal. 2019;10(2):297-312. DOI:10.20409/berj.2019.169; https://financetp.fa.ru/jour/article/view/1279Test

الإتاحة: https://doi.org/10.26794/2587-5671-2021-25-4-82-97Test
https://doi.org/10.26794/2587-5671-2021-25-4Test
https://doi.org/10.24411/2072-4098-2021-10304Test
https://doi.org/10.2308/accr.00000005Test
https://doi.org/10.1007/978-3-030-66093-2_20Test
https://doi.org/10.2308/accr-51383Test
https://doi.org/10.6000/1929-7092.2018.07.61Test
https://doi.org/10.2139/ssrn.3438533Test
https://doi.org/10.20900/jsr20210010Test
https://doi.org/10.1002/smj.2131Test

المؤلفون: V. Diomidova N., M. Safonova A., O. Zakharova V., A. Dmitrieva N., O. Efimova A., В. Диомидова Н., М. Сафонова А., О. Захарова В., А. Дмитриева Н., О. Ефимова А.

المصدر: Research and Practical Medicine Journal; Том 7, № 4 (2020); 51-61 ; Research'n Practical Medicine Journal; Том 7, № 4 (2020); 51-61 ; 2410-1893 ; 2409-2231 ; 10.17709/2409-2231-2020-7-4

مصطلحات موضوعية: magnetic resonance imaging, diffusion-weighted images, endometrium, primary multiple malignancies, магнитно-резонансная томография, диффузионно-взвешенные изображения, эндометрий, первично-множественные злокачественные новообразования

وصف الملف: application/pdf

العلاقة: https://www.rpmj.ru/rpmj/article/view/632/391Test; Рубцова Н.А., Новикова Е.Г., Синицын В.Е. Роль диффузионно-взвешенной магнитно-резонансной томографии в диагностике рецидивных опухолей матки. Радиология-практика. 2012;(4):41–54.; Hricak H, Oguz A, Sala E. Diagnostic imaging: Gynecology. Amirsys, 2007, 830 p.; Сафонова М.А., Диомидова В.Н., Захарова О.В., Ионов А.М., Сиордия А.А. Поражение женских репродуктивных органов в структуре первично-множественных злокачественных новообразований. Вопросы гинекологии, акушерства и перинатологии. 2016;15(3):48–53.; Состояние онкологической помощи населению России в 2017 году. Под ред. А.Д.Каприна, В.В.Старинского, Г.В.Петровой М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018, 236 с.; Состояние онкологической помощи населению России в 2018 году. Под ред. А.Д.Каприна, В.В.Старинского, Г.В.Петровой М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019, 236 с.; Аксель Е.М., Давыдов М.И. Статистика заболеваемости и смертности от злокачественных новообразований в 2000 году. Злокачественные новообразования в России и странах СНГ в 2000. М.: РОНЦ им. Н.Н. Блохина РАМН, 2012, 85–106 с.; Маховский В.З., Юрин С.В., Маховский В.В. Синхронное первично-множественное злокачественное поражение толстой кишки и яичника с исходом в острую кишечную непроходимость. Хирургия. Журнал им. Н.И.Пирогова. 2016;4:67–69. https://doi.org/10.17116/hirurgia2016467-69Test; Чудина А.П., Львов А.А., Крутикова И.П., Некрасова Е.А., Савлучинская Л.А. Первично-множественные злокачественные новообразования при онкологической отягощенности семейного анамнеза. Онкология. Журнал им. П.А.Герцена. 2017;6(2):29–32. https://doi.org/10.17116/onkolog20176229-32Test; Степанова Ю.А., Калинин Д.В., Вишневский В.А. Первичномножественные опухоли (обзор литературы). Медицинская визуализация. 2015;(6):93–102.; Паяниди Ю.Г., Жордания К.И., Паукер В., Сельчук В.Ю., Казубская Т.П. Первично-множественные злокачественные новообразования органов репродуктивной системы и толстой кишки у женщин. Вестник РОНЦ им. Н.Н. Блохина РАМН. 2016;27(2):108–112.; Рубцова Н.А., Новикова Е.Г. Ошибки магнитно-резонансной томографии в диагностике рака шейки матки и эндометрия. Лучевая диагностика и терапия. 2013;(3):71–76.; Рубцова Н.А., Новикова Е.Г., Синицин В.Е., Востров А.Н., Степанов С.О. Рак эндометрия: предоперационное стадирование. Сопоставление информативности ультразвукового исследования и магнитно-резонансной томографии. Вестник рентгенологии и радиологии. 2012;(4):33–41.; Zandrino F, La Paglia E, Musante F. Magnetic resonance imaging in local staging of endometrial carcinoma: diagnostic performance, pitfalls, and literature review. Tumori. 2010 Aug;96(4):601–608.; Yahata T, Aoki Y, Tanaka K. Prediction of myometrial invasion in patients with endometrial carcinoma: comparison of magnetic resonance imaging, transvaginal ultrasonography, and gross visual inspection. Eur J Gynaecol Oncol. 2007;28(3):193–195.; Padhani DM, Padhani AR, Collins DJ. Technology insight: water diffusion MRI – a potential new biomarker of response to cancer therapy. Nat Clin Pract Oncol. 2008 Apr;5(4):220–233. https://doi.org/10.1038/ncponc1073Test; Heunser T-A, Kuemmel S, Koeninger A, Hamami ME, Hahn S, Quinsten A, et al. Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging. Eur J Nucl Med Mol Imaging. 2010 Jun;37(6):1077–1086. https://doi.org/10.1007/s00259-010-1399-zTest; Ikeda Y, Saku M, Kishihara F, Maehara Y. Effective follow-up for recurrence or a second primary cancer in patients with early gastric cancer. Br J Surg. 2005 Feb;92(2):235–239. https://doi.org/10.1002/bjs.4758Test; Wu C-W, Lo S-S, Chen J-H, Hsieh M-C, Li AFY, Lui W-Y. Multiple primary cancers in patients with gastric cancer. Hepatogastroenterology. 2006 Jun;53(69):463–467.; Сафонова М.А., Диомидова В.Н. Комплексная лучевая диагностика опухолевого поражения органов малого таза при синхронных полинеоплазиях. Современные тенденции развития науки и технологий. 2015;(6-4):88–90.; Куталиа П.З., Сельчук В.Ю., Паяниди Ю.Г., Жорданиа К.И., Шелепова В.М., Захарова Т.И. Злокачественные новообразования яичников и полинеоплазии: клиника, диагностика, закономерности развития, прогноз. Опухоли женской репродуктивной системы. 2011;(1):80–85. https://doi.org/10.17650/1994-4098-2011-0-1-80-85Test; Жук Е.Г., Косенко И.А., Дударев В.С., Карман А.В., Василевский А.П., Шиманец С.В. Определение последовательности методов комплексной лучевой диагностики в оценке распространенности рака эндометрия. Актуальные вопросы диагностики и лечения злокачественных новообразований: сб. науч. работ Респ. науч.-практ. конф., посвящ. 40-летию каф. онкологии. Под общ. ред. А.В. Прохорова. Минск: БГМУ, 2014, 30–31 с.; Каприн А.Д., Галкин В.Н., Жаворонков Л.П., Иванов В.К., Иванов С.А., Романко Ю.С. Синтез фундаментальных и прикладных исследований – основа обеспечения высокого уровня научных результатов и внедрения их в медицинскую практику. Радиация и риск. 2017;26(2):26-40. https://doi.org/10.21870/0131-3878-2017-26-2-26-40Test; Petsuksiril J, Jaishuen A, Pattaranutaporn P, Chansilpa Y. Advanced imaging applications for locally advanced cervical cancer. Asian Pac J Cancer Prev. 2012;13(5):1713–1718. https://doi.org/10.7314/apjcp.2012.13.5.1713Test; https://www.rpmj.ru/rpmj/article/view/632Test

الإتاحة: https://doi.org/10.17709/2409-2231-2020-7-4-5Test
https://doi.org/10.17709/2409-2231-2020-7-4Test
https://doi.org/10.17116/hirurgia2016467-69Test
https://doi.org/10.17116/onkolog20176229-32Test
https://doi.org/10.1038/ncponc1073Test
https://doi.org/10.1007/s00259-010-1399-zTest
https://doi.org/10.1002/bjs.4758Test
https://doi.org/10.17650/1994-4098-2011-0-1-80-85Test
https://doi.org/10.21870/0131-3878-2017-26-2-26-40Test
https://doi.org/10.7314/apjcp.2012.13.5.1713Test

المؤلفون: O. Talantova E., E. Serebryakova A., O. Malysheva V., A. Tikhonov V., E. Shabanova S., O. Efimova A., O. Chiryaeva G., V. Prokhorova S., A. Glotov S., О. Талантова Е., Е. Серебрякова А., О. Малышева В., А. Тихонов В., Е. Шабанова С., О. Ефимова А., О. Чиряева Г., В. Прохорова С., А. Глотов С.

المصدر: Medical Genetics; Том 19, № 3 (2020); 53-54 ; Медицинская генетика; Том 19, № 3 (2020); 53-54 ; 2073-7998

مصطلحات موضوعية: трисомия 2, пренатальная диагностика, хромосомный микроматричный анализ (arrayCGH), синдром задержки развития плода (СЗРП), маловодие, долихоцефалия, вентрикуломегалия, trisomy 2, prenatal diagnosis, chromosomal microarray analysis (arrayCGH), fetal growth retardation syndrome (FGR), oligohydramnios, dolichocephaly, ventriculomegaly

وصف الملف: application/pdf

العلاقة: https://www.medgen-journal.ru/jour/article/view/830/502Test; https://www.medgen-journal.ru/jour/article/view/830Test

الإتاحة: https://doi.org/10.25557/2073-7998.2020.03.53-54Test
https://www.medgen-journal.ru/jour/article/view/830Test

المؤلفون: P. Kozyulina Y., E. Vashukova S., A. Morshneva V., N. Dvoinova M., O. Tarasenko E., O. Talantova E., A. Koroteev L., D. Ivanov O., E. Serebryakova A., E. Shabanova S., A. Pendina A., A. Tikhonov V., O. Chiryaeva G., O. Efimova A., T. Ivashchenko E., V. Baranov S., A. Glotov S., П. Козюлина Ю., Е. Вашукова С., А. Моршнева В., Н. Двойнова М., О. Тарасенко Е., О. Талантова Е., А. Коротеев Л., Д. Иванов О., Е. Серебрякова А., Е. Шабанова С., А. Пендина А., А. Тихонов В., О. Чиряева Г., О. Ефимова А., Т. Иващенко Э., В. Баранов С., А. Глотов С.

المصدر: Medical Genetics; Том 19, № 3 (2020); 71-73 ; Медицинская генетика; Том 19, № 3 (2020); 71-73 ; 2073-7998

مصطلحات موضوعية: пренатальная диагностика, хромосомная патология, НИПТ, prenatal diagnosis, chromosomal pathology, NIPT

وصف الملف: application/pdf

العلاقة: https://www.medgen-journal.ru/jour/article/view/838/510Test; https://www.medgen-journal.ru/jour/article/view/838Test

الإتاحة: https://doi.org/10.25557/2073-7998.2020.03.71-73Test
https://www.medgen-journal.ru/jour/article/view/838Test

المؤلفون: І. L. Visochina, N. S. Bashkirova, N. O. Efimova

المصدر: Medičnì Perspektivi, Vol 23, Iss 1(part2), Pp 22-25 (2018)

مصطلحات موضوعية: constipation, treatment of the constipation, Medicine

وصف الملف: electronic resource

العلاقة: http://journals.uran.ua/index.php/2307-0404/article/view/126935Test; https://doaj.org/toc/2307-0404Test

الوصول الحر: https://doaj.org/article/9f516b4fb4a6430e80034b420b6f8a95Test

المؤلفون: V. G. Konkov, V. S. Kudrin, V. B. Narkevich, A. O. Efimova, T. D. Nikiforova, L. G. Kolik

المصدر: Neurochemical Journal. 16:85-91

مصطلحات موضوعية: Cellular and Molecular Neuroscience, Molecular Biology, Biochemistry

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::d41ba4aab4b63ee2649f11c6043ab467Test
https://doi.org/10.1134/s1819712422010081Test

المؤلفون: O. Efimova I., T. Pavlova V., О. Ефимова И., Т. Павлова В.

المصدر: Translational Medicine; Том 5, № 6 (2018); 10-22 ; Трансляционная медицина; Том 5, № 6 (2018); 10-22 ; 2410-5155 ; 2311-4495 ; 10.18705/2311-4495-2018-5-6

مصطلحات موضوعية: atrial fibrillation, oral anticoagulants, stroke, thromboembolic complications, risk factors, hemorrhagic complications, фибрилляция предсердий, оральные антикоагулянты, инсульт, тромбоэмболические осложнения, факторы риска, геморрагические осложнения

وصف الملف: application/pdf

العلاقة: https://transmed.almazovcentre.ru/jour/article/view/444/321Test; https://transmed.almazovcentre.ru/jour/article/downloadSuppFile/444/425Test; https://transmed.almazovcentre.ru/jour/article/downloadSuppFile/444/426Test; https://transmed.almazovcentre.ru/jour/article/downloadSuppFile/444/427Test; https://transmed.almazovcentre.ru/jour/article/downloadSuppFile/444/428Test; https://transmed.almazovcentre.ru/jour/article/downloadSuppFile/444/429Test; Алферова В.В., Белкин А.А., Вознюк И.А. и др. Клинические рекомендации по ведению больных с ишемическим инсультом и транзиторными ишемическими атаками. / под ред. В. И. Скворцовой Москва 2017, с 208.; Снижение заболеваемости, смертности и инвалидности от инсультов в Российской Федерации : сб. метод. рек. / под ред. В. И. Скворцовой; Минздравсоцразвития РФ, ГОУ "РГМУ", НИИ инсульта. - Москва: Литтерра, 2008. - 192 с: табл.; Adams HP Jr, Bendixen BH, Kappele LJ et al. Classification of sybtype of acute stroke: Definituin for use in a multicentre clinical trial, TOAST, Trial of Org 10172 in Acute Stroke Treatment. Stroke.1993; 24(1):35–41.; Кузнецов А.Н., Виноградов О.И., Кучеренко С.С. Ишемический инсульт. Диагностика. Лечение. Профилактика: карманный справочник. Mосква: РАЕН; 2012.; Наnna JP, Furlan AJ. Cardiac disease and embolic sources. Brain ischemia: Basic concepts and clinical relevalence. Caplan-Lond LD, editor. Springer-Verlag. 1995; 299–315.; Choudhury A, Lip GY. Atrial fibrillation and the hypercoagulable state: from basic science to clinical practice. Pathophysiol Haemost Thromb 2003–2004; 33: 282–89.; Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857–867.; Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955–962.; Lip GY, Laroche C, Ioachim PM, et al. Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EUR Observational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry). Eur Heart J 2014; 35:3365–3376.; Kirchhof P, Ammentorp B, Darius H, et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events—European Registry in Atrial Fibrillation (PREFER in AF). Europace 2014; 16:6–14.; Nabauer M, Gerth A, Limbourg T, et al. The Registry of the German Competence NETwork on Atrial Fibrillation: Patient characteristics and initial management. Europace 2009; 11:423–434.; Kirchhof P, Nabauer M, Gerth A, et al. Impact of the type of centre on management of AF patients: surprising evidence for differences in antithrombotic therapy decisions. Thromb Haemost 2011; 105:1010–1023.; Alonso-Coello P, Montori VM, Sola I, et al. Values and preferences in oral anticoagulation in patients with atrial fibrillation, physicians’ and patients’ perspectives: protocol for a two-phase study. BMC Health Serv Res 2008; 8:221.; Lip GY, Al-Khatib SM, Cosio FG, et al. Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches? J Am Heart Assoc 2014; 3:e001179.; Gorst-Rasmussen A, Skjoth F, Larsen TB, et al. Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. J Thromb Haemost 2015;13: 495–504.; Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137:263–272.; Lip GY, Lane DA. Modern management of atrial fibrillation requires initial identification of “low-risk” patients using the CHA2DS2-VASc score, and not focusing on “high-risk” prediction. Circ J 2014; 78:1843–1845.; Lip GY, Lane DA. Stroke prevention in atrial fibrillation: a systematic review. JAMA 2015; 313:1950–1962.; Pisters R, Lane DA, Nieuwlaat R, et al. A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138:1093–1100.; Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151:713–719.; Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011; 58:395–401.; Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012; 33:1500–1510.; Hijazi Z, Oldgren J, Lindback J, et al. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet 2016; 387:2302–2311.; ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367:1903–1912.; Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 360:2066–2078.; Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364:806–817.; Mant J, Hobbs FD, Fletcher K, et al.Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370:493–503.; van Walraven C, Hart RG, Connolly S, Austin PC, et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke 2009; 40:1410–1416.; Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fbrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37:2893–2962. doi:10.1093/eurheartj/ehw210.; Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139–1151.; Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363:1875–1876.; Graham DJ, Reichman ME,Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015; 131:157–164.; Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883–891.; Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981–992.; Hylek EM, Held C, Alexander JH, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol 2014; 63:2141–2147.; Flaker GC, Eikelboom JW, Shestakovska O, et al. Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) trial. Stroke 2012; 43:3291–3297.; Hohnloser SH, Pajitnev D, Pogue J, et al. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. J Am Coll Cardiol 2007; 50:2156–2161.; Friberg L, Hammar N, Pettersson H, et al. Increased mortality in paroxysmal atrial fibrillation: report from the Stockholm Cohort-Study of Atrial Fibrillation (SCAF). Eur Heart J 2007; 28:2346–2353.; Vanassche T, Lauw MN, Eikelboom JW, et al. Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. Eur Heart J 2015; 36: 281–288.; Steinberg BA, Hellkamp AS, Lokhnygina Y, et al. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. Eur Heart J 2015; 36: 288–296.; Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012; 366:120–129.; Binici Z, Intzilakis T, Nielsen OW, et al. Excessive supraventricular ectopic activity and increased risk of atrial fibrillation and stroke. Circulation 2010; 121:1904–1911.; Hans-Christoph Diener, James Aisenberg, Jack Anse, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part1. European Heart Journal, 2016 doi:10.1093/eurheartj/ehv643; Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369:2093–2104.; Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17:1467–1507.; Paciaroni M, Agnelli G. Should oral anticoagulants be restarted after warfarin-associated cerebral haemorrhage in patients with atrial fibrillation? Thromb Haemost 2014; 111:14–18.; Kuramatsu JB, Gerner ST, Schellinger PD, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulationrelated intracerebral hemorrhage. JAMA 2015; 313:824–836.; Nielsen PB, Larsen TB, Skjoth F, et al. Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality, and Bleeding: A Nationwide Cohort Study. Circulation 2015; 132:517–525.; Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123:2363–2372.; Vaughan Sarrazin MS, Jones M, Mazur A, et al. Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran. Am J Med 2014; 127:1179–1185.; Hernandez I, Baik SH, Pinera A, et al. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Internal Medicine 2015; 175:18–24.; Abraham NS, Singh S, Alexander GC, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ 2015; 350:h1857.; Chang HY, Zhou M, TangW, et al. Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study. BMJ 2015; 350:h1585.; Larsen TB, Gorst-Rasmussen A, Rasmussen LH, et al. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. Am J Med 2014; 127:650–656 e5, doi:10.1016/ j.amjmed.2014.01.031.; Larsen TB, Rasmussen LH, Skjoth F, et al. Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013; 61:2264–2273.; Chan EW, Lau WC, Leung WK, et al. Prevention of dabigatran-related gastrointestinal bleeding with gastroprotective agents: a population-based study. Gastroenterology 2015; 149:586–595.e3.; Goodman SG, Wojdyla DM, Piccini JP, et al. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol 2014; 63:891–900.; Halperin JL, Hankey GJ, Wojdyla DM, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation 2014; 130: 138–146.; Piccini JP, Garg J, Patel MR, et al. Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. Eur Heart J 2014; 35:1873–1880.; Hori M, Matsumoto M, Tanahashi N, et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study. Circ J 2012; 76:2104–2111.; Laliberte F, Cloutier M, Nelson WW, et al. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin 2014; 30:1317–1325.; Piccini JP, Stevens SR, Chang Y, et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation 2013; 127:224–232.; Eikelboom JW, Connolly SJ, Gao P, et al. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. J Stroke Cerebrovasc Dis 2012; 21:429–435.; Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011; 32:2387–2394.; Hijazi Z, Hohnloser SH, Oldgren J, et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation 2014; 129:961–970.; Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012; 33:2821–2830.; Bohula EA, Giugliano RP, Ruff CT, et al. Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 Trial. Circulation 2016; 134: 24–36.; Jan Steffel, Peter Verhamme, Tatjana S. Potpara, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal (2018) 00, 1–64 doi:10.1093/eurheartj/ehy136; Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation 2013; 127:634–640.; Rubboli A, Faxon DP, Juhani Airaksinen KE, et al. The optimal management of patients on oral anticoagulation undergoing coronary artery stenting. The 10th Anniversary Overview. Thromb Haemost 2014; 112: 1080–1087.; Mega JL, Braunwald E, Mohanavelu S, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009; 374:29–38.; Sarafoff N, Martischnig A,Wealer J, et al. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol 2013; 61:2060–2066.; Jackson LR II, Ju C, Zettler M, et al. Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study. JACC Cardiovasc Interv 2015; 8: 1880–1889.; Dewilde WJM, Oirbans T, Verheugt FWA, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013; 381:1107–1115.; https://transmed.almazovcentre.ru/jour/article/view/444Test

الإتاحة: https://doi.org/10.18705/2311-4495-2018-5-6-10-22Test
https://doi.org/10.18705/2311-4495-2018-5-6Test
https://doi.org/10.1093/eurheartj/ehw210Test
https://doi.org/10.1093/eurheartj/ehv643Test
https://doi.org/10.1093/eurheartj/ehy136Test
https://transmed.almazovcentre.ru/jour/article/view/444Test

المؤلفون: E. Chezganova A., O. Efimova S., S. Sozinov A., A. Efimova R., V. Sakharova M., A. Kutikhin G., M. Osnova V., Z. Ismagilov R., E. Brusina B., Е. Чезганова А., О. Ефимова С., С. Созинов А., А. Ефимова Р., В. Сахарова М., А. Кутихин Г., М. Основа В., З. Исмагилов Р., Е. Брусина Б.

المصدر: Epidemiology and Vaccinal Prevention; Том 18, № 4 (2019); 82-92 ; Эпидемиология и Вакцинопрофилактика; Том 18, № 4 (2019); 82-92 ; 2619-0494 ; 2073-3046 ; 10.31631/2073-3046-2019-18-4

مصطلحات موضوعية: Air pollution, particulate matter, hospital environment, healthcare-associated infections, reservoir, multidrug-resistant organisms, пылевое загрязнение, мелкодисперсные взвешенные вещества, больничная пыль, инфекции, связанные с оказанием медицинской помощи, резервуар, госпитальный штамм Конфликт интересов не заявлен

وصف الملف: application/pdf

العلاقة: https://www.epidemvac.ru/jour/article/view/804/564Test; Beggs C.B. The airborne transmission of infection in hospital buildings: fact or fiction? // Indoor Built Environ. 2003. N 12. P. 9–18.; Eames I., Tang J.W., Li Y., Wilson P. Airborne transmission of disease in hospitals // J R Soc Interface. 2009. N 6. P. S697–702.; Hobday R.A., Dancer S.J. Roles of sunlight and natural ventilation for controlling infection: historical and current perspectives // J Hosp Infect. 2013. Vol. 84, N 4. P. 271–82.; Sattar S.A., Ijaz M.K. The Role of Indoor Air as a Vehicle for Human Pathogens: Summary of Presentations, Knowledge Gaps, and Directions for the Future // Am J Infect Control. 2016. Vol. 44, N 9. P. 144–S146.; Surgical operations and procedures statistics. Доступно по: https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Surgical_operations_and_procedures_Test statistics#Increasing_and_decreasing_surgical_operations_and_procedures Ссылка активна на 20 июня 2019.; Hooshmand J., Allena P., Pakroua N., Votea B.J. Laminar airflow system use across the operating surface for airborne infection prevention in office-based surgical procedures // J Hosp Infect. 2018. Vol. 99, N 3. P. 308–309.; Mannucci P.M., Harari S., Martinelli I., Franchini M. Effects on health of air pollution: a narrative review // Intern Emerg Med. 2015. Vol. 10, N 6. P. 657–662.; Qian H., Zheng X. Ventilation control for airborne transmission of human exhaled bio-aerosols in buildings // J Thorac Dis. 2018. N 10, Suppl. 19. P. S2295–S2304.; Besta E., Parnella P., Couturierb J., et al. Environmental contamination by bacteria in hospital washrooms according to hand-drying method: a multi-centre study // J Hosp Infect. 2018. Vol. 100, N 4. P. 469–475.; Брико Н.И., Брусина Е.Б., Зуева Л.П. и др. Госпитальный штамм – непознанная реальность // Эпидемиология и вакцинопрофилактика. 2013. № 1 (68). С. 30–35.; Брусина Е.Б. Эпидемиология инфекций, связанных с оказанием медицинской помощи, вызванных возбудителями группы сапронозов // Эпидемиология и вакцинопрофилактика. 2015. Т. 14, № 2 (81). С. 50–56.; Zemouri C., de Soet H., Crielaard W., Laheij A. A scoping review on bio-aerosols in healthcare and the dental environment // PLoS One. 2017. Vol. 12, N 5. P. e0178007.; Chauveaux D. Preventing surgical-site infections: measures other than antibiotics // Orthop Traumatol Surg Res. 2015. Vol. 101 (Suppl). P. S77–83.; Акимкин В.Г., Покровский В.И. Нозокомиальный сальмонеллез взрослых. М.: Издательство РАМН; 2002. 136 с.; Bonifait L., Charlebois R., Vimont A., et al. Detection and quantification of airborne norovirus during outbreaks in healthcare facilities // Clin Infect Dis. 2015. Vol. 61. P. 299–304.; Sękowska A. Raoultella spp. – clinical significance, infections and susceptibility to antibiotics // Folia Microbiol (Praha). 2017. Vol. 62, N 3. P. 221–227.; Xu C., Wei M., Chen J., et al. Mellouki A Profile of inhalable bacteria in PM2.5 at Mt. Tai, China: Abundance, community, and influence of air mass trajectories // Ecotoxicol Environ Saf. 2019. Vol. 168. P. 110–119.; Hansen D., Krabs C., Benner D., et al. Laminar air flow provides high air quality in the operating field even during real operating conditions, but personal protection seems to be necessary in operations with tissue combustion // Int J Hyg Environ Health. 2005. Vol. 208, N 6. P. 455–60.; https://www.epidemvac.ru/jour/article/view/804Test

الإتاحة: https://doi.org/10.31631/2073-3046-2019-18-4-82-92Test
https://doi.org/10.31631/2073-3046-2019-18-4Test
https://www.epidemvac.ru/jour/article/view/804Test